Socio-economic burden of pulmonary hypertension: relevance of assessment in Russia and the world

Cover Page

Cite item

Full Text

Abstract

Pulmonary hypertension (PH) is a progressive disease which is characterized with the increase of pulmonary artery pressure and pulmonary vascular resistance. Such condition leads to right ventricular heart failure and premature death of patients. Pulmonary arterial hypertension (PAH) has the status of an orphan disease. However in Russia only idiopathic PH is included in the list of 24 life-threatening and chronic progressive rare diseases, while other forms of PH are not in it. Inclusion in this list guarantees drug provision for patients at the expense of the regional budget, while patients with other forms of PH can rely on free medication only if they have a disability. The lack of criteria for revising this list as well as the imperfection of legal regulation in the field of drug support for orphan diseases leads to high disability, a significant decrease in the duration and quality of life of patients with PH. As part of a multicriteria approach, a clinical and economic analysis of the disease burden can be one of the tools for policy development and decision-making on the distribution of funding in the healthcare. The article provides a review of the economic burden of various forms of PH in the world.

About the authors

V. D. Zakiev

Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology

Author for correspondence.
Email: zakiev739@gmail.com
ORCID iD: 0000-0003-4027-3727

ординатор отд. легочной гипертензии и заболеваний сердца

Russian Federation, Moscow

A. D. Gvozdeva

Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology

Email: zakiev739@gmail.com
ORCID iD: 0000-0002-5684-9842

ординатор отд. легочной гипертензии и заболеваний сердца

Russian Federation, Moscow

T. V. Martynyuk

Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology

Email: zakiev739@gmail.com
ORCID iD: 0000-0002-9022-8097

д.м.н., проф., рук. отд. легочной гипертензии и заболеваний сердца.

Russian Federation, Moscow

References

  1. Nazzareno G, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37:67-119. doi: 10.1093/eurheartj/ehv317
  2. Чазова И.Е., Авдеев С.Н., Царева Н.А. и др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив. 2014;86(9):4-23 [Chazova IE, Avdeev SN, Tsareva NA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Therapeutic Archive. 2014;86(9):4-23 (In Russ.)].
  3. Платонов Д.Ю., Царева Н.А., Авдеев С.Н. Выживаемость пациентов с легочной артериальной гипертензией на фоне терапии таблетированными ЛАГ-специфическими препаратами. Системные гипертензии. 2017;14(3):58-64 [Platonov DYu, Tsareva NA, Avdeev SN. Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs. Systemic Hypertension. 2017;14(3):58-64 (In Russ.)]. doi: 10.26442/2075-082X_14.3.58-64
  4. Иванов К.И. Стимуляторы растворимой гуанилатциклазы и ингибиторы фосфодиэстеразы 5-го типа в терапии некоторых форм легочной гипертензии. Пульмонология. 2017;27(6):803-10. doi: 10.18093/0869-0189-2017-27-6-803-810 [Ivanov KI. Soluble guanylate cyclase stimulants and type 5 phosphodiesterase inhibitors in the treatment of certain forms of pulmonary hypertension. Pulmonology. 2017;27(6):803-10 (In Russ.)]. doi: 10.18093/0869-0189-2017-27-6-803-810
  5. Постановление Правительства РФ от 26.04.2012 №403 (ред. от 20.11.2018) «О порядке ведения Федерального регистра лиц, страдающих жизнеугрожающими и хроническими прогрессирующими редкими (орфанными) заболеваниями, приводящими к сокращению продолжительности жизни граждан или их инвалидности, и его регионального сегмента» [Decree of the Government of the Russian Federation from April 26, 2012 No. 403 (as amended on November 20, 2018) “On the Procedure for Maintaining the Federal Register of Persons Suffering Life-threatening and Chronic Progressing Rare (Orphan) Diseases, Leading to a Reduction in the Life Duration of Citizens or Their Disability, and Its Regional segment“ (In Russ.)].
  6. Игнатьева В.И., Авксентьева М.В. Анализ методологических особенностей исследований по изучению социально-экономического бремени заболеваний в РФ в рамках разработки стандартной методики анализа стоимости болезни с целью ее использования в оценке технологий здравоохранения. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2014;7(3) [Ignatieva VI, Avksentieva MV. An analysis of the methodological features of research on the socio-economic burden of disease in the Russian Federation as part of the development of a standard methodology for analyzing the cost of a disease with a view to its use in assessing healthcare technologies. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2014;7(3) (In Russ.)].
  7. Основные понятия в оценке медицинских технологий. Методическое пособие. Под общ. ред. А.С. Колбина, С.К. Зырянова, Д.Ю. Белоусова. М.: ОКИ, 2013 [Basic concepts of medical technology evaluation. Toolkit. Ed. A.S. Kolbina, S.K. Zyryanova, D.Yu. Belousova. Moscow: OKI, 2013 (In Russ.)].
  8. Хабриев Р.У., Ягудина Р.И., Правдюк Н.Г. Оценка технологий здравоохранения. М.: Медицинское информационное агентство, 2013 [Khabriev RU, Yagudina RI, Pravdyuk NG. Health technology assessment. Moscow: Medical News Agency, 2013 (In Russ.)].
  9. Оценка медицинских технологий. Международный опыт. Под ред. В.И. Стародубова, И.Н. Каграманяна. М., 2012 [Assessment of medical technology. International experience. Ed. V.I. Starodubova, I.N. Kahramanyan. Moscow, 2012 (In Russ.)].
  10. Омельяновский В.В., Авксентьева М.В., Деркач Е.В. и др. Анализ стоимости болезни – проблемы и пути решения. Педиатрическая фармакология. 2011;3:6-12 [Omel’yanovskii VV, Avksent’eva MV, Derkach EV, et al. Analysis of the cost of the disease – problems and solutions. Pediatric pharmacology. 2011;8(3):6-12 (In Russ.)].
  11. Ягудина Р.И., Серпик В.Г. Методология анализа затрат. Фармакоэкономика: теория и практика. 2016;4(2):5-9 [Yagudina RI, Serpik VG. Cost Analysis Methodology. Pharmacoeconomics: theory and practice. 2016;4(2):5-9. doi: 10.30809/phe.2.2016.8 (In Russ.)].
  12. Методические рекомендации по расчету затрат при проведении клинико-экономических исследований лекарственных препаратов. М.: ФГБУ ЦЭККМП, 2018 [Guidelines for calculating costs in conducting clinical and economic studies of drugs. Moscow: FGBU CEKKMP, 2018 (In Russ.)]. https://rosmedex.ru/wp-content/uploads/2019/06/MR-AVB_novaya-redaktsiya_2018-g..pdf
  13. Серпик В.Г., Аринина Е.Е. Фармакоэкономический анализ средств лечения легочной артериальной гипертензии в Российской Федерации. Фармакоэкономика: теория и практика. 2016;4(3):40-6 [Serpik VG, Arinina EE. Pharmacoeconomic analysis of the treatment of pulmonary arterial hypertension in the Russian Federation. Pharmacoeconomics: theory and practice. 2016;4(3):40-6. doi: 10.30809/phe.3.2016.4 (In Russ.)].
  14. Burger CD, Ghandour M, Padmanabhan Menon D, et al. Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. Clinicoecon Outcomes Res. 2017;9:731-9.
  15. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improved functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108(17):2066-9.
  16. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004;24(6):1007-10.
  17. Burke JP, Hunsche E, Regulier E, et al. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. Am J Manag Care. 2015;21(3 Suppl.):s47-s58.
  18. Kirson NY, Birnbaum HG, Ivanova JI, et al. Excess Costs Associated with Patients with Pulmonary Arterial Hypertension in a US Privately Insured Population. Appl Health Econ Health Policy. 2011;9(5):293-303. doi: 10.2165/11592430-000000000-00000
  19. Said Q, Martin BC, Joish VN, et al. The cost to managed care of managing pulmonary hypertension. J Med Econ. 2012;15:500-8.
  20. Angalakuditi M, Edgell E, Beardsworth A, et al. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. J Med Econ. 2010;13(3):393-402. doi: 10.3111/13696998.2010.496694
  21. Gu S, Hu H, Dong H. Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension. PharmacoEconomics. 2015;34(6):533-50. doi: 10.1007/s40273-015-0361-0
  22. Copher R, Cerulli A, Watkins A, Laura MM. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. J Med Econ. 2012;15:947-55.
  23. Sikirica M, Iorga SR, Bancroft T, Potash J. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res. 2014;14:676.
  24. Burger CD, Ozbay AB, Lazarus HM, et al. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. J Manag Care Spec Pharm. 2018;24(8):834-42. doi: 10.18553/jmcp.2018.17391
  25. Studer S, Edmonds Y, Hull M, et al. Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database. Pulm Circ. 2018;9(1):2045894018816294. doi: 10.1177/2045894018816294
  26. Dufour R, Pruett J, Hu N, et al. Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class. J Med Econ. 2017;20:1178-86. doi: 10.1080/13696998.2017.1363049
  27. Rely K, Pulido Zamudio T, Escamilla C, et al. Direct health care costs in patients with pulmonary arterial hypertension in the national institute of cardiology «ignacio chávez» (nic), Mexico city. Value Health. 2013;16(3):A189. doi: 10.1016/j.jval.2013.03.950
  28. Wilkens H, Grimminger F, Hoeper M, et al. Burden of pulmonary arterial hypertension in Germany. Respir Med. 2010;104:902-10.
  29. Kirson NY, Birnbaum HG, Ivanova JI, et al. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a U.S. privately insured population. Appl Health Econ Health Policy. 2011;9(6):377-87.
  30. Чазова И.Е., Мартынюк Т.В., Валиева З.С. и др. Оценка бремени хронической тромбоэмболической легочной гипертензии в Российской Федерации. Терапевтический архив. 2018;90(9):101-9 [Chazova IE, Martynyuk TV, Valieva ZS, et al. The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation. Therapeutic Archive. 2018;90(9):101-9 (In Russ.)]. doi: 10.26442/terarkh2018909101-109
  31. UK National Specialised Commissioning Team. Service Specification 2011/2012.
  32. Schweikert B, Pittrow D, Vizza CD, et al. Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries. BMC Health Serv Res. 2014;14:246. doi: 10.1186/1472-6963-14-246
  33. Joish V, Divers C, Burudpakdee C, et al. What Costs Can a U.S. Health Plan Expect if an Enrollee Has Chronic Thromboembolic Pulmonary Hypertension? A Guideline-Based Estimate of Healthcare Resource Use and Cost. Chest. 2014;145(3):523A. doi: 10.1378/chest.1821901
  34. Heresi GA, Platt DM, Wang W, et al. Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia. BMC Pulm Med. 2017;17(1):58.
  35. Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю. и др. Анализ стоимости болезни сахарного диабета 2 типа в Российской Федерации: результаты Российского многоцентрового наблюдательного фармакоэпидемиологического исследования ФОРСАЙТ-СД2. Сахарный диабет. 2017;20(6):403-19 [Dedov II, Kalashnikova MF, Belousov DY, et al. Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-Т2DM). Diabetes mellitus. 2017;20(6):403-19 (In Russ.)]. doi: 10.14341/DM9278
  36. Концевая А.В, Калинина А.М., Колтунов И.Е., Оганов Р.Г. Социально-экономический ущерб от острого коронарного синдрома в Российской Федерации. Рациональная фармакотерапия в кардиологии. 2011;7(2):158-66 [Kontsevaya AV, Kalinina AM, Koltunov IE, Oganov RG. Socio-economic damage from acute coronary syndrome in the Russian Federation. State Research Center for Preventive Medicine. Rational pharmacotherapy in cardiology. 2011;7(2):158-66 (In Russ.)].
  37. Колбин А.С., Татарский Б.А., Бисерова И.Н. и др. Социально-экономическое бремя мерцательной аритмии в Российской Федерации. Клиническая фармакология и терапия. 2010;19(4):17-22 [Kolbin AS, Tatarsky BA, Biserova IN, et al. Socio-economic burden of atrial fibrillation in the Russian Federation. Clinical pharmacology and therapy. 2010;19(4):17-22 (In Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies